COPD: The most common adverse reactions reported for Trelegy Ellipta 100/62.5/25 mcg (incidence ≥1%) are upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, headache, back pain ...
CAPTAIN (C linical study of A sthma P atients receiving T riple therapy through A single IN haler) was a randomised, double-blind, active controlled, six-arm parallel group, global multicentre study ...
Results from a phase 3 trial evaluating Trelegy Ellipta in patients with uncontrolled asthma showed that the single inhaler triple therapy provided a significant improvement in lung function when ...
GSK plc announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium ...
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...
(MENAFN- GlobeNewsWire - Nasdaq) SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for ...
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...
GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results